Vectibix 'effekt hos patienter med metastatisk colorectal cancer (mCRC), der havde sygdomsprogression under eller efter tidligere kemoterapi, blev undersøgt i et randomiseret, kontrolleret forsøg (463 patienter) og open- label, enkeltgruppe- forsøg (384 patienter).
The efficacy of Vectibix in patients with metastatic colorectal cancer (mCRC) who had disease progression during or after prior chemotherapy was studied in a randomised controlled trial (463 patients) and open-label, single-arm trials (384 patients).